Christophe Weber, Takeda CEO (Shoko Takayasu/Bloomberg via Getty Images)
October 26, 2023 07:30 AM EDTUpdated 10:23 AM
Pharma

Take­da takes $770M write­down on failed stem cell ther­a­py and with­drawn can­cer drug

Katherine Lewin

News Reporter

Take­da record­ed $2.4 bil­lion (369.7 bil­lion yen) in amor­ti­za­tion and im­pair­ment loss­es in its fi­nan­cial re­port for the first half of fis­cal year 2023, a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis claims best earn­ings in years, val­i­dat­ing shift to pure-play strat­e­gy

Roche sep­a­rates CFO, in­for­mat­ics posts; Lil­ly ex­ecs land at Kail­era, Neu­ro­crine

Ver­tex's non-opi­oid pain drug is ap­proved by FDA, bring­ing first of new class to mar­ket

Fri­day IPO dou­ble­head­er from Maze and Met­sera brings life to biotech de­buts

Ab­b­Vie rais­es Skyrizi and Rin­voq es­ti­mates, pre­dicts $31B in 2027 sales

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times